Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

FDA Approves Exenatide Extended-Release Injection for T2D

FDA Approves Exenatide Extended-Release Injection for T2D

By

The new formulation of Bydureon BCise allows for once-weekly administration with an autoinjector pen.

Drug Label Updated to Include Time Action Profile for Rapid-Acting Inhaled Insulin

Drug Label Updated to Include Time Action Profile for Rapid-Acting Inhaled Insulin

By

The prescribing information for Afrezza has been updated to include new clinical data relating to treatment effect and dosing.

Predicting Emergency Department or Hospital Visits in T2D Adverse Events

Predicting Emergency Department or Hospital Visits in T2D Adverse Events

By

Over 150 variables were identified as possible hypoglycemia risk factors.

GSK Announces Discontinuation of Injectable Therapy for T2D

GSK Announces Discontinuation of Injectable Therapy for T2D

By

GlaxoSmithKline expects Tanzeum supplies to be depleted by July 2018.

Centrally-Acting Opioid Linked to Case of Rebound Hypoglycemia in Type 1 Diabetes

Centrally-Acting Opioid Linked to Case of Rebound Hypoglycemia in Type 1 Diabetes

By

The patient became severely hypoglycemic within 10 to 12 hours after taking the pain drug.

More Articles by Diana Ernst, RPh

Sign Up for Free e-Newsletters

CME Focus